Journal Scans
Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer
Neoadjuvant Bevacizumab in HER2-Negative Breast Cancer
G von Minckwitz, H Eidtmann, M Rezai, P Fasching, H Tesch, H Eggemann, I Schrader, K Kittel, C Hanusch, R Kreienberg, C Solbach, B Gerber, C Jackisch, G Kunz, J Blohmer, J Huober, M Hauschild, T Fehm, B Maria Muller, C Denkert, S Loibl, V Nekljudova, M Untch
Yes
20120026
2012 Jan 26
N Engl J Med
Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer
N Engl J Med. 2012 Jan 26;366(4):299-309, G von Minckwitz, H Eidtmann, M Rezai, P Fasching, H Tesch, H Eggemann, I Schrader, K Kittel, C Hanusch, R Kreienberg, C Solbach, B Gerber, C Jackisch, G Kunz, J Blohmer, J Huober, M Hauschild, T Fehm, B Maria Muller, C Denkert, S Loibl, V Nekljudova, M Untch
TAKE-HOME MESSAGE
EXPERT COMMENTARY
Abstract
SUMMARY
OncologySTAT Editorial Team
Neoadjuvant chemotherapy with anthracyclines, taxanes, and anti-HER2 agents results in complete tumor response at the time of surgery in 30% to 40% of patients with human epidermal growth factor receptor 2 (HER2)-positive or triple-negative (estrogen– and progesterone–receptor negative, and no overexpression of HER2) breast cancer. Pathologic complete response is correlated with low rates of relapse and death in this patient population. This paper evaluated the efficacy of bevacizumab in patients...
